$0.68
1.17% yesterday
Nasdaq, Nov 14, 10:00 pm CET
ISIN
US54303L1044
Symbol
LGVN

Longeveron Inc - Ordinary Shares - Class A Stock price

$0.68
-0.12 14.79% 1M
-0.67 49.50% 6M
-1.05 60.60% YTD
-1.40 67.23% 1Y
-38.92 98.28% 3Y
-99.32 99.32% 5Y
-99.32 99.32% 10Y
-99.32 99.32% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
-0.01 1.17%
ISIN
US54303L1044
Symbol
LGVN
Industry

Key metrics

Basic
Market capitalization
$14.5m
Enterprise Value
$5.3m
Net debt
positive
Cash
$9.2m
Shares outstanding
21.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
10.1 | 11.5
EV/Sales
3.7 | 4.3
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
85.6%
Return on Equity
-112.5%
ROCE
-208.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.4m | $1.3m
EBITDA
$-21.0m | -
EBIT
$-22.2m | $-22.3m
Net Income
$-21.3m | $-25.6m
Free Cash Flow
$-17.4m
Growth (TTM | estimate)
Revenue
-22.2% | -46.3%
EBITDA
-23.2% | -
EBIT
-23.3% | -35.1%
Net Income
22.0% | -3.8%
Free Cash Flow
-11.3%
Margin (TTM | estimate)
Gross
74.9%
EBITDA
-1,459.9% | -
EBIT
-1,542.7%
Net
-1,485.1% | -1,990.9%
Free Cash Flow
-1,209.2%
More
EPS
$-1.2
FCF per Share
$-0.8
Short interest
9.1%
Employees
25
Rev per Employee
$100.0k
Show more

Is Longeveron Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,041 stocks worldwide.

Longeveron Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Longeveron Inc - Ordinary Shares - Class A forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Longeveron Inc - Ordinary Shares - Class A forecast:

Buy
89%
Hold
11%

Financial data from Longeveron Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1.44 1.44
22% 22%
100%
- Direct Costs 0.36 0.36
28% 28%
25%
1.08 1.08
20% 20%
75%
- Selling and Administrative Expenses 12 12
11% 11%
829%
- Research and Development Expense 11 11
36% 36%
785%
-21 -21
23% 23%
-1,457%
- Depreciation and Amortization 1.19 1.19
25% 25%
83%
EBIT (Operating Income) EBIT -22 -22
23% 23%
-1,540%
Net Profit -21 -21
22% 22%
-1,482%

In millions USD.

Don't miss a Thing! We will send you all news about Longeveron Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Longeveron Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
3 days ago
The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging No approved treatments for aging-related frailty, a syndrome affecting older individuals that impairs human Healthspan, and is characterized by weakness, low physical activity, slowed motor performance, exh...
Neutral
Seeking Alpha
10 days ago
Longeveron Inc. ( LGVN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Than Powell - Interim CEO & Director Nataliya Agafonova - Chief Medical Officer Devin Blass - CTO & Senior VP of Chemistry, Manufacturing, and Controls Lisa Locklear - CFO, Executive VP & Treasurer Joshua Hare - Co-Founder, Chief Science Officer & Executive Chairman Conference Call Participants Dere...
Neutral
GlobeNewsWire
19 days ago
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indication ELPIS II top-line trial results are anticipated in the thi...
More Longeveron Inc - Ordinary Shares - Class A News

Company Profile

Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers in October 9, 2014 and is headquartered in Miami, FL.

Head office United States
CEO Mohamed Hashad
Employees 25
Founded 2014
Website www.longeveron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today